IL6 and metabolic dysfunction-associated steatotic liver disease: Anyhow, this target-based Mendelian randomization suggested the potential risk of NAFLD caused by inhibiting the classic IL-6 signaling, which should be paid attention to in patients receiving anti-IL6R treatments.